Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Similar presentations


Presentation on theme: "Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma."— Presentation transcript:

1 Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy  Lawrence D. Kaplan, Steven R. Deitcher, Jeffrey A. Silverman, Gareth Morgan  Clinical Lymphoma, Myeloma and Leukemia  Volume 14, Issue 1, Pages (February 2014) DOI: /j.clml Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure 1 Time to Progression and Overall Survival in Heavily Pretreated Patients With Advanced Relapsed and Refractory DLBCL and MCL. Circles Indicate Time to Progression; Squares Indicate Overall Survival in the DLBCL and MCL Patients Receiving VSLI Plus Rituximab Abbreviations: DLBCL = diffuse large B-cell lymphoma; MCL = mantle cell lymphoma; VSLI = vincristine sulfate liposome injection. Clinical Lymphoma, Myeloma and Leukemia  , 37-42DOI: ( /j.clml ) Copyright © 2014 Elsevier Inc. Terms and Conditions


Download ppt "Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma."

Similar presentations


Ads by Google